Long-term study of ALKS 2680 for narcolepsy and idiopathic hypersomnia
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study continues treatment with the investigational drug ALKS 2680 for people who have already completed a previous ALKS 2680 study for narcolepsy or idiopathic hypersomnia. It aims to see how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the end-of-treatment visit in a qualifying earlier study of ALKS 2680 (such as Vibrance or Brilliance studies).
- You must be willing and able to stop any current narcolepsy medications for about 5 half-lives before starting and for the whole study, if your doctor agrees it's safe.
- You must not have developed any new significant health condition, ECG, or lab abnormality that could affect your participation.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not be enrolled in any other clinical study or have used an investigational drug or device within 30 days before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
This trial is for people who have already completed the main CRYSTAL-1 study of ORX750. It tests the long-term safety and effects of the drug, so you can continue treatment if it was helping you.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
Hear when a new Narcolepsy Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.